Drug intelligence / Profile preview

Jinying Sizi Tiaotai

Development stage: Preclinical
Administration: Oral

Overview

Jinying Sizi Tiaotai is a traditional Chinese medicine (TCM) prescription. It is referenced in clinical research as an intervention for patients with type 2 diabetes, often in combination with semaglutide injection. The specific herbal composition, mechanism of action, and pharmacological details are not provided in the available sources. Its use appears to be as an adjunct therapy within integrative medicine approaches for metabolic disorders such as type 2 diabetes[1].

Other names: Jinying Sizi Tiaotai

Beyond the preview

Go deeper on Jinying Sizi Tiaotai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jinying Sizi Tiaotai.

Explore the full profile